Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.60 |
| ▸ | REN | P00797 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | PEPD | P12955 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13019815 | 1.00 | ACE (0.60) | ACERENKDM4EF2LMNA | |
| SCHEMBL19817050 | 1.00 | ACE (0.60) | ACERENKDM4EF2LMNA | |
| SCHEMBL30517412 | 0.90 | ACE (0.47) | ACERENKDM4EF2LMNA | |
| SCHEMBL16656669 | 0.87 | PREP (0.47) | ACERENKDM4EF2LMNA | |
| SCHEMBL16021695 | 0.85 | ACE (0.59) | ACERENKDM4EF2LMNA | |
| SCHEMBL11376437 | 0.84 | PREP (0.62) | ACERENKDM4EF2LMNA | |
| SCHEMBL7363556 | 0.84 | ACE (0.61) | ACERENKDM4EF2LMNA | |
| SCHEMBL11376449 | 0.84 | PREP (0.62) | ACERENKDM4EF2LMNA | |
| SCHEMBL17305538 | 0.84 | DPP4 (0.61) | ACERENKDM4EF2LMNA | |
| SCHEMBL7329608 | 0.84 | ACE (0.61) | ACERENKDM4EF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563127-B | Compounds, agents and uses thereof | 麦特博隆股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-10865183-B2 | Compounds, reagents, and uses thereof | METABOLON, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3491004-A1 | DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF | Metabolon, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190152907-A1 | COMPOUNDS, REAGENTS, AND USES THEREOF | METABOLON, INC. | 2019-05-23 | — | — | US | disclosed |
| WO-2018022866-A1 | DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF | METABOLON, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| US-4736066-A | Intermediate for substituted peptide compounds | E. R. SQUIBB & SONS, INC. (US) | 1988-04-05 | — | — | US | disclosed |
| US-4535176-A | HYPOTENSIVE AGENTS, ANALGESICS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1985-08-13 | — | — | US | disclosed |
| US-4470973-A | HYPOTENSIVE AGENTS, ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1984-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865183-B2 | Compounds, reagents, and uses thereof | REN, ATP6V1B1, PKD1 | ACE 316/4885REN 1/4885KDM4E 3199/4885 |
| US-20190152907-A1 | COMPOUNDS, REAGENTS, AND USES THEREOF | REN, ATP6V1B1, PKD1 | ACE 316/4885REN 1/4885KDM4E 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.